PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Letrozole

Drugs in development · updated 30 October 2026

Letrozole: clinical trials and development status

Other names and codes: oral Femara

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Letrozole is in 151 active clinical trials (recruiting or ongoing, phases I–III) for 33 diseases. The most advanced phase is III.

151Active trials
IIIMost advanced phase
33Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Letrozole and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 33 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Breast neoplasmIII101NCT07894328
Endometrial neoplasmII–III13NCT05316935
NeoplasmIII6NCT04906395
MetastasisIII5NCT06757634
Ovarian neoplasmIII5NCT04095364
Fallopian tube neoplasmIII4NCT04095364
Endometrial hyperplasiaII–III3NCT05316935
Male breast neoplasmIII3NCT05827081
Progesterone resistanceII–III3NCT05316935
Breast diseaseIII2NCT04964934
Ectopic pregnancyII–III2NCT07842796
InfertilityIII2NCT03011684
Intraductal carcinoma of the breastIII2NCT01272037
ObesityII–III2NCT06379113
Ovarian epithelial carcinomaIII2NCT05601700
AnovulationIII1NCT07616973
Inflammatory breast cancerII–III1NCT02221999
Peritoneal neoplasmIII1NCT04111978
Polycystic Ovary SyndromeIII1NCT07616973
Unilateral breast neoplasmIII1NCT06760637
Triple-negative breast neoplasmII4NCT05582499
Head and neck neoplasmsII2NCT05226871
Head and neck squamous cell carcinomaII2NCT05226871
Breast lobular carcinomaII1NCT02764541
HemangiosarcomaII1NCT01042379
Lung small cell carcinomaII1NCT04553133
Non-small-cell lung carcinomaII1NCT04606446
Prostatic NeoplasmsI–II1NCT07288359
Serous cystadenocarcinomaII1NCT03673124
Uterine cervix neoplasmI–II1NCT05768139

Everything on Letrozole

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch